Assessing the impact of socio-economic determinants on access to care, surgical treatment options and outcomes among patients with renal mass: Insight from the universal healthcare system.

cancer minimally invasive surgery partial nephrectomy radical nephrectomy socio-economic disparities universal healthcare

Journal

European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979

Informations de publication

Date de publication:
Nov 2022
Historique:
revised: 07 04 2022
received: 14 07 2021
accepted: 05 07 2022
pubmed: 24 7 2022
medline: 30 11 2022
entrez: 23 7 2022
Statut: ppublish

Résumé

To assess whether socio-economic disparities exist on access to care, treatment options and outcomes among patients with renal mass amenable of surgical treatment within the universal healthcare system. Data of consecutive patients submitted to partial nephrectomy (PN) or radical nephrectomy (RN) at our Institution between 2017 and 2020 were retrospectively evaluated. Patients were grouped according to their income level (low, intermediate, and high) based on the Indicator of Equivalent Economic Situation national criterion. Survival analysis was performed. Cox regression models were employed to analyse the impact of socio-economic variables on survival outcomes. One thousand forty-two patients were included (841 PN and 201 RN). Patients at the lowest income level were found more likely symptomatic and with a higher pathological tumour stage in the RN cohort (p > 0.05). The guidelines adherence on surgical indication rate as well as the access to minimally invasive surgery did not differ according to patient's income level in both cohorts (p > 0.05). Survival curves were comparable among the groups. Cox regression analysis showed that none of the included socio-economic variables was associated with survival outcomes in our series. Universal healthcare system may increase the possibility to ensure egalitarian treatment modalities for patients with renal cancer.

Identifiants

pubmed: 35869594
doi: 10.1111/ecc.13666
pmc: PMC9787702
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e13666

Informations de copyright

© 2022 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd.

Références

J Robot Surg. 2018 Mar;12(1):35-41
pubmed: 28247092
Urology. 2015 Jun;85(6):1411-6
pubmed: 25881864
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
Urology. 2015 Nov;86(5):892-9
pubmed: 26291563
Urology. 2016 Apr;90:69-74
pubmed: 26724412
BJU Int. 2020 Jul;126(1):114-123
pubmed: 32232920
Eur Urol. 2017 Apr;71(4):606-617
pubmed: 27614693
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13666
pubmed: 35869594
Cancer. 2012 Sep 15;118(18):4421-6
pubmed: 22298310
Cancer Med. 2016 Feb;5(2):200-8
pubmed: 26710924
Clin Genitourin Cancer. 2012 Dec;10(4):219-24
pubmed: 22749689
World J Urol. 2013 Oct;31(5):1211-7
pubmed: 22622394
Eur Urol. 2020 Jul;78(1):21-28
pubmed: 32376137
JAMA Netw Open. 2020 Jan 3;3(1):e1919185
pubmed: 31940036
Eur Urol. 2009 Nov;56(5):786-93
pubmed: 19665284
J Clin Oncol. 2012 Jan 10;30(2):142-50
pubmed: 22147735
Urol Oncol. 2019 Mar;37(3):182.e17-182.e27
pubmed: 30630732
Minerva Urol Nephrol. 2021 Dec;73(6):773-780
pubmed: 33200901
N Engl J Med. 2008 Jun 5;358(23):2468-81
pubmed: 18525043
J Urol. 2022 Apr;207(4):937-938
pubmed: 34981950
J Urol. 2020 Mar;203(3):496-504
pubmed: 31609167
CA Cancer J Clin. 2020 Jan;70(1):31-46
pubmed: 31661164
J Clin Oncol. 2018 Jan 1;36(1):25-33
pubmed: 29035642
Eur Urol. 2018 Aug;74(2):226-232
pubmed: 29784191
Urology. 2021 Jan;147:21-26
pubmed: 32979378
Urology. 2020 Oct;144:123-129
pubmed: 32603743
Int J Urol. 2022 Jul;29(7):667
pubmed: 35384069
BJU Int. 2020 Jan;125(1):73-81
pubmed: 31293036
Am J Surg Pathol. 2013 Oct;37(10):1490-504
pubmed: 24025520
Actas Urol Esp (Engl Ed). 2020 Nov;44(9):637-638
pubmed: 32843151
Minerva Urol Nephrol. 2021 Aug;73(4):540-543
pubmed: 33200907
Eur Urol. 2021 Oct;80(4):428-439
pubmed: 33218826
Eur Urol Focus. 2021 Mar;7(2):390-396
pubmed: 31727523

Auteurs

Antonio Andrea Grosso (AA)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Fabrizio Di Maida (F)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Riccardo Tellini (R)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Lorenzo Viola (L)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Luca Lambertini (L)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Francesca Valastro (F)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Andrea Mari (A)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Lorenzo Masieri (L)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Marco Carini (M)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Andrea Minervini (A)

Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH